GlobeNewswire: Biothera Pharmaceuticals, Inc. Contains the last 10 of 24 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:45:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/11/1959602/0/en/Biothera-Pharmaceuticals-Presents-Updated-Phase-2-Data-for-Chemo-refractory-Triple-Negative-Breast-Cancer-Patients-at-San-Antonio-Breast-Cancer-Symposium.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Presents Updated Phase 2 Data for Chemo-refractory Triple Negative Breast Cancer Patients at San Antonio Breast Cancer Symposium2019-12-11T23:00:00Z<![CDATA[EAGAN, Minn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that updated response and clinical benefit data from its ongoing Phase 2 study in chemo-refractory metastatic triple negative breast cancer (mTNBC) patients were presented during a Spotlight Session at the 2019 San Antonio Breast Cancer Symposium (SABCS).]]>https://www.globenewswire.com/news-release/2019/12/04/1956198/0/en/Biothera-Pharmaceuticals-Phase-2-Triple-Negative-Breast-Cancer-Data-Selected-for-Spotlight-Session-at-San-Antonio-Breast-Cancer-Symposium.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Phase 2 Triple Negative Breast Cancer Data Selected for Spotlight Session at San Antonio Breast Cancer Symposium2019-12-04T14:00:00Z<![CDATA[EAGAN, Minn., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that response and clinical benefit data from its Phase 2 study of dectin-1 agonist Imprime PGG in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in chemo-refractory metastatic triple negative breast cancer patients have been selected for a poster discussion Spotlight Session on December 11 at the 2019 San Antonio Breast Cancer Symposium.]]>https://www.globenewswire.com/news-release/2019/11/08/1943938/0/en/Biothera-Pharmaceuticals-to-Present-Immune-Pharmacodynamic-Data-IPD-Showing-Immune-Activation-in-Phase-2-Melanoma-and-Triple-Negative-Breast-Cancer-Study.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals to Present Immune Pharmacodynamic Data (IPD) Showing Immune Activation in Phase 2 Melanoma and Triple Negative Breast Cancer Study2019-11-08T12:00:00Z<![CDATA[Two Late-Breaking Poster Presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting]]>https://www.globenewswire.com/news-release/2019/11/05/1941317/0/en/Biothera-Pharmaceuticals-to-Present-Immune-Pharmacodynamic-and-Survival-Data-from-Phase-2-Melanoma-and-Triple-Negative-Breast-Cancer-Study.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study2019-11-05T15:00:00Z<![CDATA[Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting Two Late-Breaking Poster Presentations Set for November 8 and 9 at Society for Immunotherapy of Cancer (SITC) Annual Meeting]]>https://www.globenewswire.com/news-release/2019/06/01/1862904/0/en/Biothera-Pharmaceuticals-Presents-Clinical-Data-from-Phase-2-Study-Evaluating-the-Combination-of-Imprime-PGG-and-Merck-s-KEYTRUDA-in-Triple-Negative-Breast-Cancer-at-2019-ASCO-Annu.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting2019-06-01T13:00:00Z<![CDATA[EAGAN, Minn., June 01, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today primary data from IMPRIME 1, a Phase 2 clinical trial evaluating Imprime PGG, Biothera’s dectin receptor agonist, and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc. (known as MSD outside the United States and Canada), in chemo-refractory metastatic triple negative breast cancer (mTNBC) patients. The findings will be highlighted in a poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, June 1 from 8:00 AM-11:00 AM Central Time.]]>https://www.globenewswire.com/news-release/2019/05/16/1826310/0/en/Biothera-Pharmaceuticals-to-Present-Clinical-Data-from-Phase-2-Triple-Negative-Breast-Cancer-Study-at-ASCO-2019-Annual-Meeting.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting2019-05-16T14:00:00Z<![CDATA[Study Evaluating Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® Study Evaluating Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA®]]>https://www.globenewswire.com/news-release/2018/09/05/1565738/0/en/Biothera-Pharmaceuticals-Announces-Immuno-Oncology-Clinical-Trial-Collaboration-with-AstraZeneca.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca2018-09-05T13:15:00Z<![CDATA[Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer]]>https://www.globenewswire.com/news-release/2018/05/16/1507712/0/en/Biothera-Pharmaceuticals-Appoints-Andrew-D-C-LaFrence-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer2018-05-16T20:10:10Z<![CDATA[EAGAN, Minn., May 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective May 29. Biothera Pharmaceuticals is a clinical stage immuno-oncology company developing a novel immunotherapy in combination with immune checkpoint inhibitors for multiple types of cancer.]]>https://www.globenewswire.com/news-release/2018/04/16/1472070/0/en/Biothera-Pharmaceuticals-Presents-Translational-Data-from-Ongoing-Clinical-Trials-Showing-Imprime-PGG-in-Combination-with-Merck-s-KEYTRUDA-pembrolizumab-Drives-Innate-and-Adaptive-.html?f=22&fvtc=4&fvtv=30774Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors2018-04-16T13:00:00Z<![CDATA[EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada). These data provide the first evidence in human clinical trials that Imprime PGG-based therapy can activate the immune system at the tumor site in cancer patients. Pre- and on-treatment tumor biopsy data supporting this activity were presented in a late-breaking poster at the ongoing American Association for Cancer Research (AACR) annual meeting taking place in Chicago, IL, April 14-18, 2018.]]>https://www.globenewswire.com/news-release/2018/03/26/1453019/0/en/Preclinical-Data-Showing-Synergy-of-Biothera-Pharmaceuticals-Imprime-PGG-and-a-CD40-Agonist-in-a-Pancreatic-Cancer-Model-Presented-at-Keystone-Symposia.html?f=22&fvtc=4&fvtv=30774Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia2018-03-26T14:00:00Z<![CDATA[EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical data demonstrating the combination of Imprime PGG and a CD40 agonist antibody stimulated T cell-dependent anti-tumor activity in a pancreatic cancer model. The data were presented at the ongoing Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada.]]>